Press Room

2007 Press Releases

TSX:V - IXS
NASD OTC:BB: IXSBF

September 18, 2007

InNexus Biotechnology CEO to Give Keynote Presentation at 18th Annual Wall Street Analyst Forum

British Columbia, Canada - September 18, 2007 - InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that Jeff Morhet, Chairman and CEO, will be the keynote speaker at The Wall Street Analyst Forum, being held at the Princeton Club in New York City on Thursday, September 20, 2007. Mr. Morhet is scheduled to present at 8:30 AM ET in the amphitheater. The presentation will include an overview of the Company’s business strategy and future milestones. InNexus’ Chief Financial Officer, Wade Brooksby, will also be in attendance.

The presentation can be viewed through a live web cast and archived shortly after the event. The web cast will be available at: www.wsw.com/webcast

About DXL™ Technology

DXL™ technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. This may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. In addition, DXL™ antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. To learn more about InNexus' DXL™ technology, please visit www.ixsbio.com.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact

InNexus Biotechnology Inc.
Dr. Thomas Kindt, Chief Scientific Officer
480-862-7500

The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com